These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

375 related items for PubMed ID: 30080131

  • 1. Vincristine, irinotecan, and temozolomide treatment for refractory/relapsed pediatric solid tumors: A single center experience.
    Büyükkapu Bay S, Kebudi R, Görgün O, Zülfikar B, Darendeliler E, Çakır FB.
    J Oncol Pharm Pract; 2019 Sep; 25(6):1343-1348. PubMed ID: 30080131
    [Abstract] [Full Text] [Related]

  • 2. Irinotecan-temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised, phase 2 trial.
    Mody R, Naranjo A, Van Ryn C, Yu AL, London WB, Shulkin BL, Parisi MT, Servaes SE, Diccianni MB, Sondel PM, Bender JG, Maris JM, Park JR, Bagatell R.
    Lancet Oncol; 2017 Jul; 18(7):946-957. PubMed ID: 28549783
    [Abstract] [Full Text] [Related]

  • 3. A phase I trial of metformin in combination with vincristine, irinotecan, and temozolomide in children with relapsed or refractory solid and central nervous system tumors: A report from the national pediatric cancer foundation.
    Metts JL, Trucco M, Weiser DA, Thompson P, Sandler E, Smith T, Crimella J, Sansil S, Thapa R, Fridley BL, Llosa N, Badgett T, Gorlick R, Reed D, Gill J.
    Cancer Med; 2023 Feb; 12(4):4270-4281. PubMed ID: 36151773
    [Abstract] [Full Text] [Related]

  • 4. [Irinotecan plus temozolomide in refractory or relapsed pediatric solid tumors].
    Hernández-Marqués C, Lassaletta-Atienza A, Ruiz Hernández A, Blumenfeld Olivares JA, Arce Abaitua B, Cormenzana Carpio M, Madero Lopez L.
    An Pediatr (Barc); 2013 Aug; 79(2):68-74. PubMed ID: 23332825
    [Abstract] [Full Text] [Related]

  • 5. Vincristine, Irinotecan, and Temozolomide as a Salvage Regimen for Relapsed or Refractory Sarcoma in Children and Young Adults.
    Ju HY, Park M, Lee JA, Park HJ, Park SY, Kim JH, Kang HG, Yang HC, Park BK.
    Cancer Res Treat; 2022 Apr; 54(2):563-571. PubMed ID: 34126703
    [Abstract] [Full Text] [Related]

  • 6. Disparity in Outcomes for Adolescent and Young Adult Patients Diagnosed With Pediatric Solid Tumors Across 4 Decades.
    Chen I, Pasalic D, Fischer-Valuck B, Frangoul H, DeWees T, Shinohara ET, Perkins SM.
    Am J Clin Oncol; 2018 May; 41(5):471-475. PubMed ID: 27841802
    [Abstract] [Full Text] [Related]

  • 7. Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma.
    Raciborska A, Bilska K, Drabko K, Chaber R, Pogorzala M, Wyrobek E, Polczyńska K, Rogowska E, Rodriguez-Galindo C, Wozniak W.
    Pediatr Blood Cancer; 2013 Oct; 60(10):1621-5. PubMed ID: 23776128
    [Abstract] [Full Text] [Related]

  • 8. Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial.
    Corbacioglu S, Lode H, Ellinger S, Zeman F, Suttorp M, Escherich G, Bochennek K, Gruhn B, Lang P, Rohde M, Debatin KM, Steinbach D, Beilken A, Ladenstein R, Spachtholz R, Heiss P, Hellwig D, Tröger A, Koller M, Menhart K, Riemenschneider MJ, Zoubaa S, Kietz S, Jakob M, Sommer G, Heise T, Hundsdörfer P, Kühnle I, Dilloo D, Schönberger S, Schwabe G, von Luettichau I, Graf N, Schlegel PG, Frühwald M, Jorch N, Paulussen M, Schneider DT, Metzler M, Leipold A, Nathrath M, Imschweiler T, Christiansen H, Schmid I, Crazzolara R, Niktoreh N, Cario G, Faber J, Demmert M, Babor F, Fröhlich B, Bielack S, Bernig T, Greil J, Eggert A, Simon T, Foell J.
    Lancet Oncol; 2024 Jul; 25(7):922-932. PubMed ID: 38936379
    [Abstract] [Full Text] [Related]

  • 9. Pilot study of vincristine, oral irinotecan, and temozolomide (VOIT regimen) combined with bevacizumab in pediatric patients with recurrent solid tumors or brain tumors.
    Wagner L, Turpin B, Nagarajan R, Weiss B, Cripe T, Geller J.
    Pediatr Blood Cancer; 2013 Sep; 60(9):1447-51. PubMed ID: 23630159
    [Abstract] [Full Text] [Related]

  • 10. Irinotecan and temozolomide chemotherapy in paediatric and adult populations with relapsed Ewing Sarcoma.
    Salah S, To YH, Khozouz O, Ismail T, Yaser S, Alnsour A, Shahin O, Sultan I, Abuhijlih R, Halalsheh H, Abuhijla F, Lewin J.
    Clin Transl Oncol; 2021 Apr; 23(4):757-763. PubMed ID: 32761317
    [Abstract] [Full Text] [Related]

  • 11. Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: a Children's Oncology Group phase I consortium study.
    Wagner LM, Perentesis JP, Reid JM, Ames MM, Safgren SL, Nelson MD, Ingle AM, Blaney SM, Adamson PC.
    Pediatr Blood Cancer; 2010 Apr; 54(4):538-45. PubMed ID: 20049936
    [Abstract] [Full Text] [Related]

  • 12. Treatment of multiply relapsed wilms tumor with vincristine, irinotecan, temozolomide and bevacizumab.
    Venkatramani R, Malogolowkin MH, Mascarenhas L.
    Pediatr Blood Cancer; 2014 Apr; 61(4):756-9. PubMed ID: 24115645
    [Abstract] [Full Text] [Related]

  • 13. Longer versus Shorter Schedules of Vincristine, Irinotecan, and Temozolomide (VIT) for Relapsed or Refractory Ewing Sarcoma: A Randomized Controlled Phase 2 Trial.
    Xu J, Xie L, Sun X, Liu K, Liang X, Cai Z, Tang X, Guo W.
    Clin Cancer Res; 2023 Mar 14; 29(6):1040-1046. PubMed ID: 36622702
    [Abstract] [Full Text] [Related]

  • 14. Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a Children's Oncology Group Study.
    Bagatell R, Norris R, Ingle AM, Ahern C, Voss S, Fox E, Little AR, Weigel BJ, Adamson PC, Blaney S.
    Pediatr Blood Cancer; 2014 May 14; 61(5):833-9. PubMed ID: 24249672
    [Abstract] [Full Text] [Related]

  • 15. Combination of bevacizumab, irinotecan, and temozolomide for refractory or relapsed neuroblastoma: Results of a phase II study.
    Modak S, Kushner BH, Basu E, Roberts SS, Cheung NK.
    Pediatr Blood Cancer; 2017 Aug 14; 64(8):. PubMed ID: 28111925
    [Abstract] [Full Text] [Related]

  • 16. Randomized Phase II Trial of Vincristine-Irinotecan With or Without Temozolomide, in Children and Adults With Relapsed or Refractory Rhabdomyosarcoma: A European Paediatric Soft Tissue Sarcoma Study Group and Innovative Therapies for Children With Cancer Trial.
    Defachelles AS, Bogart E, Casanova M, Merks JHM, Bisogno G, Calareso G, Gallego Melcon S, Gatz SA, Le Deley MC, McHugh K, Probst A, Rocourt N, van Rijn RR, Wheatley K, Minard-Colin V, Chisholm JC.
    J Clin Oncol; 2021 Sep 20; 39(27):2979-2990. PubMed ID: 34343032
    [Abstract] [Full Text] [Related]

  • 17. Management of malignant solid tumors in children.
    Pratt CB.
    Pediatr Clin North Am; 1972 Nov 20; 19(4):1141-55. PubMed ID: 4343068
    [No Abstract] [Full Text] [Related]

  • 18. VIncristine, irinotecan, and temozolomide in children and adolescents with relapsed rhabdomyosarcoma.
    Setty BA, Stanek JR, Mascarenhas L, Miller A, Bagatell R, Okcu F, Nicholls L, Lysecki D, Gupta AA.
    Pediatr Blood Cancer; 2018 Jan 20; 65(1):. PubMed ID: 28748602
    [Abstract] [Full Text] [Related]

  • 19. Irinotecan, vincristine, cisplatin, cyclophosphamide, and etoposide for refractory or relapsed medulloblastoma/PNET in pediatric patients.
    Kim H, Kang HJ, Lee JW, Park JD, Park KD, Shin HY, Ahn HS.
    Childs Nerv Syst; 2013 Oct 20; 29(10):1851-8. PubMed ID: 23748464
    [Abstract] [Full Text] [Related]

  • 20. [Chemotherapy in patients with refractory Ewing sarcoma].
    Raciborska A, Bilska K, Drabko K, Rogowska E, Chaber R, Pogorzała M, Wyrobek E, Połczyńska K, Rodriguez-Galindo C, Woźniak W.
    Med Wieku Rozwoj; 2013 Oct 20; 17(2):117-25. PubMed ID: 23988368
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.